Training Portal

This website is intended for healthcare professionals only.Welcome to the JINARC^® (tolvaptan) training website for health care professionals in Ireland.Jinarc^® is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1 to 4 at initiation of treatment with evidence of rapidly progressing disease.Otsuka has been working with the Irish regulatory authority, the Health Products Regulatory Authority (HPRA), to provide HCPs and patients with an educational programme on the safe use of JINARC^®.This program is aimed at ensuring awareness about the potential risk of hepatotoxicity associated with the use of JINARC^® and guidance on how to manage this risk, as well as the importance of pregnancy prevention prior to the initiation and during the treatment with JINARC^®. This program includes printed copies of educational materials for HCPs and patients, as well as digital versions available on this portal to view and download.Printed hard copies of the JINARC educational materials can be obtained from Otsuka by contacting Otsuka Medical Information at medical.information@otsuka-europe.com or calling +353 1 695 0725.It is recommended that the materials on this site are used in conjunction with the full Summary of Product Characteristics .▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information.The content of this website is managed by Otsuka Pharmaceuticals (U.K.) Ltd. This website is funded by Otsuka Pharmaceuticals Europe Ltd.